News | February 25, 2026
UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The approval is supported by data from three pivotal clinical trials
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
